{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:52:40Z","timestamp":1787003560766,"version":"build-2736575974"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T00:00:00Z","timestamp":1535587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T00:00:00Z","timestamp":1535587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Latanoprost is a common glaucoma medication. Here, we study longitudinal effects of sustained latanoprost treatment on intraocular pressure (IOP) in C57BL\/6J mice, as well as two potential side-effects, changes in iris pigmentation and central corneal thickness (CCT). Male C57BL\/6J mice were treated daily for 16 weeks with latanoprost. Control mice were treated on the same schedule with the preservative used with latanoprost, benzalkonium chloride (BAK), or handled, without ocular treatments. IOP and CCT were studied at pre-treatment, 2 \u201cearly\u201d time points, and 2 \u201clate\u201d time points; slit-lamp analysis performed at a late time point; and expression of corneal and iridial candidate genes analyzed at the end of the experiment. Latanoprost lowered IOP short, but not long-term. Sustained application of BAK consistently resulted in significant corneal thinning, whereas sustained treatment with latanoprost resulted in smaller and less consistent changes. Neither treatment affected iris pigmentation, corneal matrix metalloprotease expression or iridial pigment-related genes expression. In summary, latanoprost initially lowered IOP in C57BL\/6J mice, but became less effective with sustained treatment, likely due to physiological adaptation. These results identify a new resource for studying changes in responsiveness associated with long-term treatment with latanoprost and highlight detrimental effects of commonly used preservative BAK.<\/jats:p>","DOI":"10.1038\/s41598-018-31280-1","type":"journal-article","created":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T06:55:39Z","timestamp":1535093739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of sustained daily latanoprost application on anterior chamber anatomy and physiology in mice"],"prefix":"10.1038","volume":"8","author":[{"given":"Laura M.","family":"Dutca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Rudd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Galor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona K.","family":"Garvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,30]]},"reference":[{"key":"31280_CR1","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham, Y. C. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121, 2081\u20132090, https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.013 (2014).","journal-title":"Ophthalmology"},{"key":"31280_CR2","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.2147\/OPTH.S59162","volume":"8","author":"A Alm","year":"2014","unstructured":"Alm, A. Latanoprost in the treatment of glaucoma. Clin Ophthalmol 8, 1967\u20131985, https:\/\/doi.org\/10.2147\/OPTH.S59162 (2014).","journal-title":"Clin Ophthalmol"},{"key":"31280_CR3","unstructured":"LATANOPROST ophthalmic solution 0.005% [package insert], Bausch\u2009+\u2009Lomb, a division of Valeant Pharmaceuticals North America LLC, Bridgewater, NJ (2016)."},{"key":"31280_CR4","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1097\/IJG.0000000000000158","volume":"25","author":"R Chen","year":"2016","unstructured":"Chen, R. et al. Meta-analysis of the Efficacy and Safety of Latanoprost Monotherapy in Patients With Angle-closure Glaucoma. J Glaucoma 25, e134\u2013144, https:\/\/doi.org\/10.1097\/ijg.0000000000000158 (2016).","journal-title":"J Glaucoma"},{"key":"31280_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10384-005-0293-x","volume":"50","author":"Y Ikeda","year":"2006","unstructured":"Ikeda, Y. et al. Latanoprost nonresponders with open-angle glaucoma in the Japanese population. Jpn J Ophthalmol 50, 153\u2013157, https:\/\/doi.org\/10.1007\/s10384-005-0293-x (2006).","journal-title":"Jpn J Ophthalmol"},{"key":"31280_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1089\/jop.2015.0086","volume":"32","author":"K Inoue","year":"2016","unstructured":"Inoue, K., Setogawa, A. & Tomita, G. Nonresponders to Prostaglandin Analogs Among Normal-Tension Glaucoma Patients. J Ocul Pharmacol Ther 32, 90\u201396, https:\/\/doi.org\/10.1089\/jop.2015.0086 (2016).","journal-title":"J Ocul Pharmacol Ther"},{"key":"31280_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/01.ijg.0000212214.18018.41","volume":"15","author":"L Rossetti","year":"2006","unstructured":"Rossetti, L. et al. An evaluation of the rate of nonresponders to latanoprost therapy. J Glaucoma 15, 238\u2013243, https:\/\/doi.org\/10.1097\/01.ijg.0000212214.18018.41 (2006).","journal-title":"J Glaucoma"},{"key":"31280_CR8","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1034\/j.1600-0420.1999.770318.x","volume":"77","author":"L Martin","year":"1999","unstructured":"Martin, L. Clinical experience with latanoprost: a retrospective study of 153 patients. Acta Ophthalmol Scand 77, 336\u2013339 (1999).","journal-title":"Acta Ophthalmol Scand"},{"key":"31280_CR9","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2147\/OPTH.S44708","volume":"8","author":"K Inoue","year":"2014","unstructured":"Inoue, K. Managing adverse effects of glaucoma medications. Clin Ophthalmol 8, 903\u2013913, https:\/\/doi.org\/10.2147\/OPTH.S44708 (2014).","journal-title":"Clin Ophthalmol"},{"key":"31280_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/14740338.6.1.45","volume":"6","author":"G Hollo","year":"2007","unstructured":"Hollo, G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf 6, 45\u201352, https:\/\/doi.org\/10.1517\/14740338.6.1.45 (2007).","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl 1","key":"31280_CR11","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1016\/j.survophthal.2008.08.004","volume":"53","author":"A Alm","year":"2008","unstructured":"Alm, A., Grierson, I. & Shields, M. B. Side effects associated with prostaglandin analog therapy. Survey of ophthalmology 53(Suppl 1), S93\u2013105, https:\/\/doi.org\/10.1016\/j.survophthal.2008.08.004 (2008).","journal-title":"Survey of ophthalmology"},{"key":"31280_CR12","first-page":"1134","volume":"42","author":"JW Stjernschantz","year":"2001","unstructured":"Stjernschantz, J. W. & From, P. G. F. 2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture. Invest Ophthalmol Vis Sci 42, 1134\u20131145 (2001).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"31280_CR13","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1001\/archopht.1987.01060080114039","volume":"105","author":"K Crawford","year":"1987","unstructured":"Crawford, K. & Kaufman, P. L. Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2. alpha. Arch Ophthalmol 105, 1112\u20131116 (1987).","journal-title":"alpha. Archives ophthalmology"},{"key":"31280_CR14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/0014-4835(89)90011-0","volume":"48","author":"SF Nilsson","year":"1989","unstructured":"Nilsson, S. F., Samuelsson, M., Bill, A. & Stjernschantz, J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. Exp Eye Res 48, 707\u2013716 (1989).","journal-title":"Exp Eye Res"},{"key":"31280_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/jop.1994.10.177","volume":"10","author":"DF Woodward","year":"1994","unstructured":"Woodward, D. F. et al. Studies on the ocular hypotensive effects of prostaglandin F2 alpha ester prodrugs and receptor selective prostaglandin analogs. J Ocul Pharmacol 10, 177\u2013193 (1994).","journal-title":"J Ocul Pharmacol"},{"key":"31280_CR16","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.2460\/ajvr.2000.61.1220","volume":"61","author":"ME Studer","year":"2000","unstructured":"Studer, M. E., Martin, C. L. & Stiles, J. Effects of 0.005% latanoprost solution on intraocular pressure in healthy dogs and cats. Am J Vet Res 61, 1220\u20131224 (2000).","journal-title":"Am J Vet Res"},{"key":"31280_CR17","first-page":"2485","volume":"39","author":"S Dinslage","year":"1998","unstructured":"Dinslage, S., McLaren, J. & Brubaker, R. Intraocular pressure in rabbits by telemetry II: effects of animal handling and drugs. Invest Ophthalmol Vis Sci 39, 2485\u20132489 (1998).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"31280_CR18","first-page":"146","volume":"43","author":"M Aihara","year":"2002","unstructured":"Aihara, M., Lindsey, J. D. & Weinreb, R. N. Reduction of intraocular pressure in mouse eyes treated with latanoprost. Invest Ophthalmol Vis Sci 43, 146\u2013150 (2002).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"31280_CR19","first-page":"1841","volume":"42","author":"MY Avila","year":"2001","unstructured":"Avila, M. Y., Carre, D. A., Stone, R. A. & Civan, M. M. Reliable measurement of mouse intraocular pressure by a servo-null micropipette system. Invest Ophthalmol Vis Sci 42, 1841\u20131846 (2001).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"31280_CR20","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.exer.2006.08.004","volume":"83","author":"S Husain","year":"2006","unstructured":"Husain, S., Whitlock, N. A., Rice, D. S. & Crosson, C. E. Effects of latanoprost on rodent intraocular pressure. Exp Eye Res 83, 1453\u20131458, https:\/\/doi.org\/10.1016\/j.exer.2006.08.004 (2006).","journal-title":"Exp Eye Res"},{"key":"31280_CR21","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1167\/iovs.03-0990","volume":"45","author":"JG Crowston","year":"2004","unstructured":"Crowston, J. G., Aihara, M., Lindsey, J. D. & Weinreb, R. N. Effect of latanoprost on outflow facility in the mouse. Invest Ophthalmol Vis Sci 45, 2240\u20132245 (2004).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"31280_CR22","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/archophthalmol.2010.40","volume":"128","author":"N Honda","year":"2010","unstructured":"Honda, N. et al. Effect of latanoprost on the expression of matrix metalloproteinases and tissue inhibitor of metalloproteinase 1 on the ocular surface. Arch Ophthalmol 128, 466\u2013471, https:\/\/doi.org\/10.1001\/archophthalmol.2010.40 (2010).","journal-title":"Arch Ophthalmol"},{"key":"31280_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1089\/jop.2011.0197","volume":"29","author":"S Abe","year":"2013","unstructured":"Abe, S., Watabe, H., Takaseki, S., Aihara, M. & Yoshitomi, T. The effects of prostaglandin analogues on intracellular Ca2\u2009+\u2009in ciliary arteries of wild-type and prostanoid receptor-deficient mice. J Ocul Pharmacol Ther 29, 55\u201360, https:\/\/doi.org\/10.1089\/jop.2011.0197 (2013).","journal-title":"J Ocul Pharmacol Ther"},{"key":"31280_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1167\/tvst.2.5.3","volume":"2","author":"AL Tam","year":"2013","unstructured":"Tam, A. L., Gupta, N., Zhang, Z. & Yucel, Y. H. Latanoprost Stimulates Ocular Lymphatic Drainage: An In Vivo Nanotracer Study. Transl Vis Sci Technol 2, 3, https:\/\/doi.org\/10.1167\/tvst.2.5.3 (2013).","journal-title":"Transl Vis Sci Technol"},{"key":"31280_CR25","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/bjo.2006.105585","volume":"91","author":"T Ota","year":"2007","unstructured":"Ota, T., Aihara, M., Saeki, T., Narumiya, S. & Araie, M. The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice. Br J Ophthalmol 91, 673\u2013676, https:\/\/doi.org\/10.1136\/bjo.2006.105585 (2007).","journal-title":"Br J Ophthalmol"},{"key":"31280_CR26","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1167\/iovs.06-0100","volume":"47","author":"T Ota","year":"2006","unstructured":"Ota, T., Aihara, M., Saeki, T., Narumiya, S. & Araie, M. The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice. Invest Ophthalmol Vis Sci 47, 3395\u20133399, https:\/\/doi.org\/10.1167\/iovs.06-0100 (2006).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"31280_CR27","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1167\/iovs.05-0494","volume":"46","author":"T Ota","year":"2005","unstructured":"Ota, T., Aihara, M., Narumiya, S. & Araie, M. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci 46, 4159\u20134163, https:\/\/doi.org\/10.1167\/iovs.05-0494 (2005).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"31280_CR28","doi-asserted-by":"publisher","first-page":"4571","DOI":"10.1167\/iovs.05-0723","volume":"46","author":"JG Crowston","year":"2005","unstructured":"Crowston, J. G. et al. Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice. Invest Ophthalmol Vis Sci 46, 4571\u20134577, https:\/\/doi.org\/10.1167\/iovs.05-0723 (2005).","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Suppl 1","key":"31280_CR29","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1016\/S0039-6257(02)00307-7","volume":"47","author":"MA Johnstone","year":"2002","unstructured":"Johnstone, M. A. & Albert, D. M. Prostaglandin-induced hair growth. Surv Ophthalmol 47(Suppl 1), S185\u2013202 (2002).","journal-title":"Surv ophthalmol"},{"key":"31280_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.0906-6705.2005.00270.x","volume":"14","author":"S Sasaki","year":"2005","unstructured":"Sasaki, S., Hozumi, Y. & Kondo, S. Influence of prostaglandin F2alpha and its analogues on hair regrowth and follicular melanogenesis in a murine model. Exp Dermatol 14, 323\u2013328, https:\/\/doi.org\/10.1111\/j.0906-6705.2005.00270.x (2005).","journal-title":"Exp Dermatol"},{"key":"31280_CR31","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1755-148X.2008.00482.x","volume":"21","author":"MG Anderson","year":"2008","unstructured":"Anderson, M. G., Hawes, N. L., Trantow, C. M., Chang, B. & John, S. W. Iris phenotypes and pigment dispersion caused by genes influencing pigmentation. Pigment Cell Melanoma Res 21, 565\u2013578, https:\/\/doi.org\/10.1111\/j.1755-148X.2008.00482.x (2008).","journal-title":"Pigment Cell Melanoma Res"},{"key":"31280_CR32","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1167\/iovs.09-3429","volume":"51","author":"GD Lively","year":"2010","unstructured":"Lively, G. D. et al. Genetic dependence of central corneal thickness among inbred strains of mice. Invest Ophthalmol Vis Sci 51, 160\u2013171, https:\/\/doi.org\/10.1167\/iovs.09-3429 (2010).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"31280_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1152\/physiolgenomics.00140.2009","volume":"42","author":"GD Lively","year":"2010","unstructured":"Lively, G. D., Koehn, D., Hedberg-Buenz, A., Wang, K. & Anderson, M. G. Quantitative trait loci associated with murine central corneal thickness. Physiol Genomics 42, 281\u2013286, https:\/\/doi.org\/10.1152\/physiolgenomics.00140.2009 (2010).","journal-title":"Physiol Genomics"},{"key":"31280_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2156-2-12","volume":"2","author":"OV Savinova","year":"2001","unstructured":"Savinova, O. V. et al. Intraocular pressure in genetically distinct mice: an update and strain survey. BMC Genet 2, 12 (2001).","journal-title":"BMC Genet"},{"key":"31280_CR35","doi-asserted-by":"publisher","first-page":"e1001008","DOI":"10.1371\/journal.pgen.1001008","volume":"6","author":"CM Trantow","year":"2010","unstructured":"Trantow, C. M., Hedberg-Buenz, A., Iwashita, S., Moore, S. A. & Anderson, M. G. Elevated oxidative membrane damage associated with genetic modifiers of Lyst-mutant phenotypes. PLoS Genet 6, e1001008, https:\/\/doi.org\/10.1371\/journal.pgen.1001008 (2010).","journal-title":"PLoS Genet"},{"key":"31280_CR36","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1167\/iovs.08-2791","volume":"50","author":"CM Trantow","year":"2009","unstructured":"Trantow, C. M. et al. Lyst mutation in mice recapitulates iris defects of human exfoliation syndrome. Invest Ophthalmol Vis Sci 50, 1205\u20131214, https:\/\/doi.org\/10.1167\/iovs.08-2791 (2009).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"31280_CR37","doi-asserted-by":"publisher","first-page":"e0132804","DOI":"10.1371\/journal.pone.0132804","volume":"10","author":"D Koehn","year":"2015","unstructured":"Koehn, D., Meyer, K. J., Syed, N. A. & Anderson, M. G. Ketamine\/Xylazine-Induced Corneal Damage in Mice. PLoS One 10, e0132804, https:\/\/doi.org\/10.1371\/journal.pone.0132804 (2015).","journal-title":"PLoS One"},{"key":"31280_CR38","doi-asserted-by":"crossref","unstructured":"Robles, V. A., Antony, B. J., Koehn, D. R., Anderson, M. G. & Garvin, M. K. 3D graph-based automated segmentation of corneal layers in anterior-segment optical coherence tomography images of mice. Proceedings of SPIE Medical Imaging 2014: Biomedical Applications in Molecular, Structural, and Functional Imaging. 90380F, http:\/\/spie.org\/Publications\/Proceedings\/Paper\/10.1117\/12.2043523 (2010).","DOI":"10.1117\/12.2043523"},{"key":"31280_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-13-134","volume":"13","author":"J Ye","year":"2012","unstructured":"Ye, J. et al. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics 13, 134, https:\/\/doi.org\/10.1186\/1471-2105-13-134 (2012).","journal-title":"BMC Bioinformatics"},{"key":"31280_CR40","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1093\/nar\/gks596","volume":"40","author":"A Untergasser","year":"2012","unstructured":"Untergasser, A. et al. Primer3\u2013new capabilities and interfaces. Nucleic Acids Res 40, e115, https:\/\/doi.org\/10.1093\/nar\/gks596 (2012).","journal-title":"Nucleic Acids Res"},{"key":"31280_CR41","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1089\/jop.2013.0196","volume":"30","author":"Y Maruyama","year":"2014","unstructured":"Maruyama, Y., Mori, K., Ikeda, Y., Ueno, M. & Kinoshita, S. Effects of long-term topical prostaglandin therapy on central corneal thickness. J Ocul Pharmacol Ther 30, 440\u2013444, https:\/\/doi.org\/10.1089\/jop.2013.0196 (2014).","journal-title":"J Ocul Pharmacol Ther"},{"key":"31280_CR42","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/ICO.0b013e3182000c27","volume":"30","author":"Y Zhong","year":"2011","unstructured":"Zhong, Y., Shen, X., Yu, J., Tan, H. & Cheng, Y. The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness. Cornea 30, 861\u2013864, https:\/\/doi.org\/10.1097\/ICO.0b013e3182000c27 (2011).","journal-title":"Cornea"},{"key":"31280_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/jop.2007.0125","volume":"25","author":"M Hatanaka","year":"2009","unstructured":"Hatanaka, M., Vessani, R. M., Elias, I. R., Morita, C. & Susanna, R. Jr. The effect of prostaglandin analogs and prostamide on central corneal thickness. J Ocul Pharmacol Ther 25, 51\u201353, https:\/\/doi.org\/10.1089\/jop.2007.0125 (2009).","journal-title":"J Ocul Pharmacol Ther"},{"key":"31280_CR44","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s10384-004-0110-y","volume":"48","author":"I Grierson","year":"2004","unstructured":"Grierson, I., Jonsson, M. & Cracknell, K. Latanoprost and pigmentation. Jpn J Ophthalmol 48, 602\u2013612, https:\/\/doi.org\/10.1007\/s10384-004-0110-y (2004).","journal-title":"Jpn J Ophthalmol"},{"key":"31280_CR45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1034\/j.1600-0749.2000.130305.x","volume":"13","author":"G Prota","year":"2000","unstructured":"Prota, G., Vincensi, M. R., Napolitano, A., Selen, G. & Stjernschantz, J. Latanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgus monkeys. Pigment Cell Res 13, 147\u2013150 (2000).","journal-title":"Pigment Cell Res"},{"key":"31280_CR46","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1034\/j.1600-0420.2000.078006618.x","volume":"78","author":"J Stjernschantz","year":"2000","unstructured":"Stjernschantz, J., Ocklind, A., Wentzel, P., Lake, S. & Hu, D. N. Latanoprost-induced increase of tyrosinase transcription in iridial melanocytes. Acta Ophthalmol Scand 78, 618\u2013622 (2000).","journal-title":"Acta Ophthalmol Scand"},{"issue":"Suppl 1","key":"31280_CR47","doi-asserted-by":"publisher","first-page":"S162","DOI":"10.1016\/S0039-6257(02)00292-8","volume":"47","author":"JW Stjernschantz","year":"2002","unstructured":"Stjernschantz, J. W., Albert, D. M., Hu, D. N., Drago, F. & Wistrand, P. J. Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol 47(Suppl 1), S162\u2013175 (2002).","journal-title":"Surv Ophthalmol"},{"key":"31280_CR48","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1001\/archopht.119.6.853","volume":"119","author":"JD Lindsey","year":"2001","unstructured":"Lindsey, J. D., Jones, H. L., Hewitt, E. G., Angert, M. & Weinreb, R. N. Induction of tyrosinase gene transcription in human iris organ cultures exposed to latanoprost. Arch Ophthalmol 119, 853\u2013860 (2001).","journal-title":"Arch Ophthalmol"},{"key":"31280_CR49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/00061198-200202000-00011","volume":"11","author":"K Kashiwagi","year":"2002","unstructured":"Kashiwagi, K., Tsukamoto, K., Suzuki, M. & Tsukahara, S. Effects of isopropyl unoprostone and latanoprost on melanogenesis in mouse epidermal melanocytes. J Glaucoma 11, 57\u201364 (2002).","journal-title":"J Glaucoma"},{"key":"31280_CR50","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/aos.12550","volume":"93","author":"M Helin-Toiviainen","year":"2015","unstructured":"Helin-Toiviainen, M. et al. Conjunctival matrix metalloproteinases and their inhibitors in glaucoma patients. Acta Ophthalmol 93, 165\u2013171, https:\/\/doi.org\/10.1111\/aos.12550 (2015).","journal-title":"Acta Ophthalmol"},{"key":"31280_CR51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.exer.2011.10.017","volume":"94","author":"HY Lopilly Park","year":"2012","unstructured":"Lopilly Park, H. Y., Kim, J. H., Lee, K. M. & Park, C. K. Effect of prostaglandin analogues on tear proteomics and expression of cytokines and matrix metalloproteinases in the conjunctiva and cornea. Exp Eye Res 94, 13\u201321, https:\/\/doi.org\/10.1016\/j.exer.2011.10.017 (2012).","journal-title":"Exp Eye Res"},{"key":"31280_CR52","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jcjo.2014.10.006","volume":"50","author":"ZS Pradhan","year":"2015","unstructured":"Pradhan, Z. S. et al. Prostaglandin agonist effect on matrix metalloproteinase aqueous levels in glaucoma patients. Can J Ophthalmol 50, 6\u201310, https:\/\/doi.org\/10.1016\/j.jcjo.2014.10.006 (2015).","journal-title":"Can J Ophthalmol"},{"key":"31280_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-016-0202-8","volume":"16","author":"H Yamada","year":"2016","unstructured":"Yamada, H., Yoneda, M., Gosho, M., Kato, T. & Zako, M. Bimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases. BMC Ophthalmol 16, 26, https:\/\/doi.org\/10.1186\/s12886-016-0202-8 (2016).","journal-title":"BMC Ophthalmol"},{"key":"31280_CR54","doi-asserted-by":"publisher","first-page":"e89205","DOI":"10.1371\/journal.pone.0089205","volume":"9","author":"W Chen","year":"2014","unstructured":"Chen, W. et al. Corneal alterations induced by topical application of commercial latanoprost, travoprost and bimatoprost in rabbit. PLoS One 9, e89205, https:\/\/doi.org\/10.1371\/journal.pone.0089205 (2014).","journal-title":"PLoS One"},{"key":"31280_CR55","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1517\/14656566.2012.662219","volume":"13","author":"M Digiuni","year":"2012","unstructured":"Digiuni, M., Fogagnolo, P. & Rossetti, L. A review of the use of latanoprost for glaucoma since its launch. Expert Opin Pharmacother 13, 723\u2013745, https:\/\/doi.org\/10.1517\/14656566.2012.662219 (2012).","journal-title":"Expert Opin Pharmacother"},{"key":"31280_CR56","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/IJG.0b013e3181666557","volume":"17","author":"F Aptel","year":"2008","unstructured":"Aptel, F., Cucherat, M. & Denis, P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma 17, 667\u2013673, https:\/\/doi.org\/10.1097\/IJG.0b013e3181666557 (2008).","journal-title":"J Glaucoma"},{"key":"31280_CR57","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.ophtha.2005.01.042","volume":"112","author":"R van der Valk","year":"2005","unstructured":"van der Valk, R. et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 112, 1177\u20131185, https:\/\/doi.org\/10.1016\/j.ophtha.2005.01.042 (2005).","journal-title":"Ophthalmology"},{"key":"31280_CR58","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/IJG.0b013e3181d12dd8","volume":"19","author":"TV Johnson","year":"2010","unstructured":"Johnson, T. V., Fan, S., Zhan, G., Camras, C. B. & Toris, C. B. Efficacy and mechanisms of intraocular pressure reduction with latanoprost and timolol in participants with ocular hypertension: a comparison of 1 and 6 weeks of treatment. J Glaucoma 19, 356\u2013364, https:\/\/doi.org\/10.1097\/IJG.0b013e3181d12dd8 (2010).","journal-title":"J Glaucoma"},{"key":"31280_CR59","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/j.1442-9071.2010.02305.x","volume":"38","author":"UA Faridi","year":"2010","unstructured":"Faridi, U. A. et al. Comparative study of three prostaglandin analogues in the treatment of newly diagnosed cases of ocular hypertension, open-angle and normal tension glaucoma. Clin Exp Ophthalmol 38, 678\u2013682, https:\/\/doi.org\/10.1111\/j.1442-9071.2010.02305.x (2010).","journal-title":"Clin Exp Ophthalmol"},{"key":"31280_CR60","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1136\/bjo.2003.020826","volume":"88","author":"A Ang","year":"2004","unstructured":"Ang, A., Reddy, M. A., Shepstone, L. & Broadway, D. C. Long term effect of latanoprost on intraocular pressure in normal tension glaucoma. Br J Ophthalmol 88, 630\u2013634 (2004).","journal-title":"Br J Ophthalmol"},{"key":"31280_CR61","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ophtha.2007.07.002","volume":"115","author":"KS Lim","year":"2008","unstructured":"Lim, K. S. et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology 115, 790\u2013795 e794, https:\/\/doi.org\/10.1016\/j.ophtha.2007.07.002 (2008).","journal-title":"Ophthalmology"},{"issue":"Suppl 1","key":"31280_CR62","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1016\/j.survophthal.2008.08.010","volume":"53","author":"CB Toris","year":"2008","unstructured":"Toris, C. B., Gabelt, B. T. & Kaufman, P. L. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 53(Suppl 1), S107\u2013120, https:\/\/doi.org\/10.1016\/j.survophthal.2008.08.010 (2008).","journal-title":"Surv Ophthalmol"},{"key":"31280_CR63","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1167\/iovs.04-1527","volume":"46","author":"T Ota","year":"2005","unstructured":"Ota, T., Murata, H., Sugimoto, E., Aihara, M. & Araie, M. Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation. Invest Ophthalmol Vis Sci 46, 2006\u20132011, https:\/\/doi.org\/10.1167\/iovs.04-1527 (2005).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"31280_CR64","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0002-9394(02)01827-5","volume":"135","author":"RS Noecker","year":"2003","unstructured":"Noecker, R. S. et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 135, 55\u201363 (2003).","journal-title":"Am J Ophthalmol"},{"issue":"Suppl 1","key":"31280_CR65","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1016\/S0039-6257(02)00310-7","volume":"47","author":"K Hedman","year":"2002","unstructured":"Hedman, K. & Larsson, L. I. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients. Surv Ophthalmol 47(Suppl 1), S77\u201389 (2002).","journal-title":"Surv Ophthalmol"},{"key":"31280_CR66","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1167\/iovs.06-0472","volume":"48","author":"MH Strungaru","year":"2007","unstructured":"Strungaru, M. H., Dinu, I. & Walter, M. A. Genotype-phenotype correlations in Axenfeld-Rieger malformation and glaucoma patients with FOXC1 and PITX2 mutations. Invest Ophthalmol Vis Sci 48, 228\u2013237, https:\/\/doi.org\/10.1167\/iovs.06-0472 (2007).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"31280_CR67","doi-asserted-by":"publisher","unstructured":"Doucette, L. P. & Walter, M. A. Prostaglandins in the eye: Function, expression, and roles in glaucoma. Ophthalmic Genet, 1\u20139, https:\/\/doi.org\/10.3109\/13816810.2016.1164193 (2016).","DOI":"10.3109\/13816810.2016.1164193"},{"key":"31280_CR68","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00228-014-1769-8","volume":"71","author":"LC Gao","year":"2015","unstructured":"Gao, L. C. et al. Influence of PTGS1, PTGFR, and MRP4 genetic variants on intraocular pressure response to latanoprost in Chinese primary open-angle glaucoma patients. Eur J Clin Pharmacol 71, 43\u201350, https:\/\/doi.org\/10.1007\/s00228-014-1769-8 (2015).","journal-title":"Eur J Clin Pharmacol"},{"key":"31280_CR69","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3109\/13816810.2011.628357","volume":"33","author":"CA McCarty","year":"2012","unstructured":"McCarty, C. A., Berg, R., Patchett, R., Wilke, R. A. & Burmester, J. K. Lack of association between polymorphisms in the prostaglandin F2alpha receptor and solute carrier organic anion transporter family 2A1 genes and intraocular pressure response to prostaglandin analogs. Ophthalmic Genet 33, 74\u201376, https:\/\/doi.org\/10.3109\/13816810.2011.628357 (2012).","journal-title":"Ophthalmic Genet"},{"key":"31280_CR70","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/bjophthalmol-2013-304267","volume":"98","author":"M Sakurai","year":"2014","unstructured":"Sakurai, M., Higashide, T., Ohkubo, S., Takeda, H. & Sugiyama, K. Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene, and response to latanoprost in patients with glaucoma and ocular hypertension. Br J Ohthalmol 98, 469\u2013473, https:\/\/doi.org\/10.1136\/bjophthalmol-2013-304267 (2014).","journal-title":"Br J Ophthalmol"},{"key":"31280_CR71","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.ophtha.2007.03.025","volume":"114","author":"M Sakurai","year":"2007","unstructured":"Sakurai, M., Higashide, T., Takahashi, M. & Sugiyama, K. Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene and response to latanoprost. Ophthalmology 114, 1039\u20131045, https:\/\/doi.org\/10.1016\/j.ophtha.2007.03.025 (2007).","journal-title":"Ophthalmology"},{"key":"31280_CR72","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.ophtha.2014.12.038","volume":"122","author":"F Ussa","year":"2015","unstructured":"Ussa, F. et al. Association between SNPs of Metalloproteinases and Prostaglandin F2alpha Receptor Genes and Latanoprost Response in Open-Angle Glaucoma. Ophthalmology 122, 1040\u20131048.e1044, https:\/\/doi.org\/10.1016\/j.ophtha.2014.12.038 (2015).","journal-title":"Ophthalmology"},{"key":"31280_CR73","first-page":"361","volume":"9","author":"BJ Tripathi","year":"1992","unstructured":"Tripathi, B. J., Tripathi, R. C. & Kolli, S. P. Cytotoxicity of ophthalmic preservatives on human corneal epithelium. Lens Eye Toxic Res 9, 361\u2013375 (1992).","journal-title":"Lens Eye Toxic Res"},{"key":"31280_CR74","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijpharm.2016.06.135","volume":"511","author":"JJ Hakkarainen","year":"2016","unstructured":"Hakkarainen, J. J. et al. Acute cytotoxic effects of marketed ophthalmic formulations on human corneal epithelial cells. Int J Pharm 511, 73\u201378, https:\/\/doi.org\/10.1016\/j.ijpharm.2016.06.135 (2016).","journal-title":"Int J Pharm"},{"key":"31280_CR75","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3109\/02713683.2011.626909","volume":"37","author":"P Pellinen","year":"2012","unstructured":"Pellinen, P. et al. The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo. Curr Eye Res 37, 145\u2013154, https:\/\/doi.org\/10.3109\/02713683.2011.626909 (2012).","journal-title":"Curr Eye Res"},{"key":"31280_CR76","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/IJG.0b013e31815c5f4f","volume":"17","author":"EW Leung","year":"2008","unstructured":"Leung, E. W., Medeiros, F. A. & Weinreb, R. N. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 17, 350\u2013355, https:\/\/doi.org\/10.1097\/IJG.0b013e31815c5f4f (2008).","journal-title":"J Glaucoma"},{"key":"31280_CR77","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3109\/02713683.2011.562340","volume":"36","author":"WC Stewart","year":"2011","unstructured":"Stewart, W. C., Stewart, J. A. & Nelson, L. A. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res 36, 391\u2013398, https:\/\/doi.org\/10.3109\/02713683.2011.562340 (2011).","journal-title":"Curr Eye Res"},{"key":"31280_CR78","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2174\/1874364101408010067","volume":"8","author":"AG Actis","year":"2014","unstructured":"Actis, A. G. & Rolle, T. Ocular surface alterations and topical antiglaucomatous therapy: a review. Open Ophthalmol J 8, 67\u201372, https:\/\/doi.org\/10.2174\/1874364101408010067 (2014).","journal-title":"Open Ophthalmol J"},{"key":"31280_CR79","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/IJG.0000000000000279","volume":"25","author":"R Pinheiro","year":"2016","unstructured":"Pinheiro, R., Panfil, C., Schrage, N. & Dutescu, R. M. The Impact of Glaucoma Medications on Corneal Wound Healing. J Glaucoma 25, 122\u2013127, https:\/\/doi.org\/10.1097\/IJG.0000000000000279 (2016).","journal-title":"J Glaucoma"},{"key":"31280_CR80","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1136\/bjo.2010.189449","volume":"95","author":"H Liang","year":"2011","unstructured":"Liang, H., Pauly, A., Riancho, L., Baudouin, C. & Brignole-Baudouin, F. Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system. Br J Ophthalmol 95, 869\u2013875, https:\/\/doi.org\/10.1136\/bjo.2010.189449 (2011).","journal-title":"British J Ophthalmol"},{"key":"31280_CR81","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2147\/OPTH.S102976","volume":"10","author":"T Walimbe","year":"2016","unstructured":"Walimbe, T., Chelerkar, V., Bhagat, P., Joshi, A. & Raut, A. Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma. Clin Ophthalmol 10, 821\u2013827, https:\/\/doi.org\/10.2147\/OPTH.S102976 (2016).","journal-title":"Clin Ophthalmol"},{"key":"31280_CR82","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1167\/iovs.14-14548","volume":"55","author":"S Barabino","year":"2014","unstructured":"Barabino, S., Antonelli, S., Cimbolini, N., Mauro, V. & Bouzin, M. The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye. Invest Ophthalmol Vis Sci 55, 6499\u20136504, https:\/\/doi.org\/10.1167\/iovs.14-14548 (2014).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"31280_CR83","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/IJG.0000000000000190","volume":"25","author":"WA Schrems","year":"2016","unstructured":"Schrems, W. A. et al. The Effect of Long-term Antiglaucomatous Drug Administration on Central Corneal Thickness. J Glaucoma 25, 274\u2013280, https:\/\/doi.org\/10.1097\/IJG.0000000000000190 (2016).","journal-title":"J Glaucoma"},{"key":"31280_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-018-0033-3","author":"GW Belovay","year":"2018","unstructured":"Belovay, G. W. & Goldberg, I. The thick and thin of the central corneal thickness in glaucoma. Eye (Lond). https:\/\/doi.org\/10.1038\/s41433-018-0033-3 (2018).","journal-title":"Eye (Lond)"},{"key":"31280_CR85","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00417-003-0777-7","volume":"241","author":"P Hamard","year":"2003","unstructured":"Hamard, P. et al. In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefes Arch Clin Exp Ophthalmol 241, 1037\u20131043, https:\/\/doi.org\/10.1007\/s00417-003-0777-7 (2003).","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"31280_CR86","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1089\/jop.2008.0042","volume":"24","author":"S Husain","year":"2008","unstructured":"Husain, S., Yates, P. W. & Crosson, C. E. Latanoprost-induced changes in rat intraocular pressure: direct or indirect? J Ocul Pharmacol Ther 24, 367\u2013372, https:\/\/doi.org\/10.1089\/jop.2008.0042 (2008).","journal-title":"J Ocul Pharmacol Ther"},{"key":"31280_CR87","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1167\/iovs.05-0516","volume":"47","author":"DJ Oh","year":"2006","unstructured":"Oh, D. J. et al. Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body after latanoprost. Invest Ophthalmol Vis Sci 47, 953\u2013963, https:\/\/doi.org\/10.1167\/iovs.05-0516 (2006).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"31280_CR88","doi-asserted-by":"publisher","first-page":"5259","DOI":"10.1167\/iovs.08-3356","volume":"50","author":"YH Ooi","year":"2009","unstructured":"Ooi, Y. H., Oh, D. J. & Rhee, D. J. Effect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells. Invest Ophthalmol Vis Sci 50, 5259\u20135265, https:\/\/doi.org\/10.1167\/iovs.08-3356 (2009).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"31280_CR89","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1167\/iovs.13-13630","volume":"55","author":"L De Groef","year":"2014","unstructured":"De Groef, L., Van Hove, I., Dekeyster, E., Stalmans, I. & Moons, L. MMPs in the neuroretina and optic nerve: modulators of glaucoma pathogenesis and repair? Invest Ophthalmol Vis Sci 55, 1953\u20131964, https:\/\/doi.org\/10.1167\/iovs.13-13630 (2014).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"31280_CR90","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.18240\/ijo.2017.08.20","volume":"10","author":"M Singh","year":"2017","unstructured":"Singh, M. & Tyagi, S. C. Metalloproteinases as mediators of inflammation and the eyes: molecular genetic underpinnings governing ocular pathophysiology. Int J Ophthalmol 10, 1308\u20131318, https:\/\/doi.org\/10.18240\/ijo.2017.08.20 (2017).","journal-title":"Int J Ophthalmol"},{"key":"31280_CR91","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3109\/15376516.2010.529183","volume":"21","author":"C Sharma","year":"2011","unstructured":"Sharma, C. et al. Effect of fluoroquinolones on the expression of matrix metalloproteinase in debrided cornea of rats. Toxicol Mech Methods 21, 6\u201312, https:\/\/doi.org\/10.3109\/15376516.2010.529183 (2011).","journal-title":"Toxicol Mech Methods"},{"key":"31280_CR92","first-page":"1266","volume":"40","author":"RM Garrana","year":"1999","unstructured":"Garrana, R. M., Zieske, J. D., Assouline, M. & Gipson, I. K. Matrix metalloproteinases in epithelia from human recurrent corneal erosion. Invest Ophthalmol Vis Sci 40, 1266\u20131270 (1999).","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Suppl 2","key":"31280_CR93","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1016\/S0039-6257(97)80020-3","volume":"41","author":"PJ Wistrand","year":"1997","unstructured":"Wistrand, P. J., Stjernschantz, J. & Olsson, K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 41(Suppl 2), S129\u2013138 (1997).","journal-title":"Surv Ophthalmol"},{"key":"31280_CR94","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1345\/aph.1R229","volume":"46","author":"C Swymer","year":"2012","unstructured":"Swymer, C. & Neville, M. W. Tafluprost: the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension. Ann Pharmacother 46, 1506\u20131510, https:\/\/doi.org\/10.1345\/aph.1R229 (2012).","journal-title":"Ann Pharmacother"},{"key":"31280_CR95","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/archopht.122.7.957","volume":"122","author":"A Alm","year":"2004","unstructured":"Alm, A., Schoenfelder, J. & McDermott, J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol 122, 957\u2013965, https:\/\/doi.org\/10.1001\/archopht.122.7.957 (2004).","journal-title":"Arch ophthalmol"},{"key":"31280_CR96","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1136\/bjo.87.8.956","volume":"87","author":"T Chiba","year":"2003","unstructured":"Chiba, T. et al. Comparison of iridial pigmentation between latanoprost and isopropyl unoprostone: a long term prospective comparative study. Br J Ophthalmol 87, 956\u2013959 (2003).","journal-title":"Br J ophthalmol"},{"key":"31280_CR97","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.exer.2003.12.003","volume":"78","author":"L Smith-Thomas","year":"2004","unstructured":"Smith-Thomas, L. et al. Latanoprost-induced pigmentation in human iridial melanocytes is fibroblast dependent. Exp Eye Res 78, 973\u2013985, https:\/\/doi.org\/10.1016\/j.exer.2003.12.003 (2004).","journal-title":"Exp Eye Res"},{"key":"31280_CR98","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.exer.2015.06.019","volume":"141","author":"KA Fernandes","year":"2015","unstructured":"Fernandes, K. A. et al. Using genetic mouse models to gain insight into glaucoma: Past results and future possibilities. Exp Eye Res 141, 42\u201356, https:\/\/doi.org\/10.1016\/j.exer.2015.06.019 (2015).","journal-title":"Exp Eye Res"},{"key":"31280_CR99","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1097\/00061198-199912000-00011","volume":"8","author":"SW John","year":"1999","unstructured":"John, S. W., Anderson, M. G. & Smith, R. S. Mouse genetics: a tool to help unlock the mechanisms of glaucoma. J Glaucoma 8, 400\u2013412 (1999).","journal-title":"J Glaucoma"},{"key":"31280_CR100","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000000911","author":"MG Anderson","year":"2018","unstructured":"Anderson, M. G., Meyer, K. J., Hedberg-Buenz, A. & Fingert, J. H. Update on Animal Models of Exfoliation Syndrome. J Glaucoma. https:\/\/doi.org\/10.1097\/IJG.0000000000000911 (2018).","journal-title":"J Glaucoma"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31280-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31280-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31280-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T03:56:39Z","timestamp":1671594999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31280-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,30]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["31280"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-31280-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,30]]},"assertion":[{"value":"22 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13088"}}